Setting sail: Atara raises $38.5m for Amgen spin-outs
This article was originally published in Scrip
Atara Biotherapeutics raised $38.5m in a Series B venture capital round to launch its three drug development ships – the Nina, Pinta and Santa Maria – with drug candidates from Amgen for protein energy wasting associated with end-stage renal disease and ovarian cancer.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.